Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Abroad (travel likely)RecruitingPHASE2
Conditions
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Resectable Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Second Primary Squamous Cell Carcinoma of the Head and Neck
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Brigham and Women's Hospital, Boston, Massachusetts, United States
Contact: Principal Investigator (Kartik Sehgal, MD)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study leads
Kartik Sehgal, MD
Principal Investigator
Dana-Farber Cancer Institute